Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 18:41:07 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Reliance, Wipro, ONGC, Sona BLW, Tata Power, JSW Steel, Max Healthcare Institute, Vedanta stocks in focus
- Reliance Industries, HDFC AMC, Pfizer among 103 NSE stocks to touch 52-week lows; 22 hit 52-week highs
- Recap 2023- From postpartum depression to Alzheimer’s disease, here are some crucial USFDA approvals this year
- Asian shares track Wall Street lower amid chorus of Federal Reserve speakers
- Reliance Industries AGM- Update on Jio listing, 5G roll-out among things to watch for
- Bajaj Finance Rating- ‘Sell’ - Strong performance from company in Q4
- ATF and commercial LPG prices cut
- Bank Nifty loses momentum, Nifty unable to top highs; VIX key to future movements, optimistic of recovery
- Average onion price in Delhi touches Rs 78 per kg; all-India average rate at Rs 50